Table 2.
Charateristics of study populaticon during treatment phase.
| Raw means | Adjusted meansa | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Placebo | Sertraline | Placebo | Sertraline | Sertraline v. Placebo | |||||
|
|
|
|
|
||||||
| Variables | Nondepb n = 12 | Depc n = 9 | Nondepb n = 11 | Depc n = 10 | Nondepb n = 12 | Depc n = 9 | Nondepb n = 11 | Depc n = 10 | % Differenced |
| Depressive behavior freq/h | 0.55 (0.91) | 4.60(1.0) | 0.08 (0.95) | 5.85(1.0) | 1.25(0.83) | 3.41(1.0) | 0.78(0.87) | 5.31(0.90) | 30.9 |
| Body weight kg | 4.24 (0.24) | 2.86 (0.27) | 3.96 (0.25) | 3.04 (0.26) | 3.78(0.08) | 3.65(0.09) | 3.42(0.08) | 3.47(0.08) | − 7.23 |
| Body mass index kg/m2 | 53.7(2.3) | 39.9(2.7) | 45.2(2.4) | 39.6(2.5) | 46.4(1.3) | 44.7(1.4) | 44.9(1.2) | 44.5(1.3) | −1.84 |
| Lean mass kg | 2.91 (0.12) | 2.27 (0.14) | 3.07 (0.12) | 2.52 (0.13) | 2.73(0.05) | 2.80(0.07) | 2.66(0.06) | 2.70(0.05) | −2.97 |
| Percent lean mass % | 69.6(2.2) | 77.7(2.5) | 76.7(2.3) | 81.2(2.4) | 73.1(1.2) | 76.4(1.4) | 77.2(1.2) | 77.5(1.3) | 7.19 |
| Fat mass kg | 1.29 (0.16) | 0.55 (0.19) | 0.83 (0.17) | 0.46 (0.18) | 0.97(0.06) | 0.79(0.07) | 0.71(0.06) | 0.75(0.07) | − 17.6 |
| Percent Fat Mass % | 26.8(2.3) | 18.3(2.6) | 19.5(2.4) | 14.6(2.5) | 23.0(1.3) | 19.7(1.4) | 18.9(1.3) | 18.5(1.4) | − 12.4 |
| Abdominal fat volume cm3 | 46.5(6.0) | 17.2(7.0) | 20.0(6.3) | 7.99(6.6) | 33.7(3.0) | 26.1(3.3) | 17.3(2.9) | 18.4(3.2) | − 40.3 |
| Visceral abdominal fat volume cm3 | 20.2(2.7) | 9.22(3.1) | 11.1(2.8) | 4.22(2.9) | 15.9(1.9) | 12.7(2.1) | 9.81(1.9) | 7.64(2.0) | − 38.9 |
| Subcutaneous abdominal fat Volume cm3 | 23.0(4.0) | 7.08(4.6) | 9.37(4.2) | 3.63(4.6) | 14.6(1.5) | 12.4(1.6) | 8.45(1.4) | 10.6(1.7) | − 29.3 |
| Visceral: subcutaneous abdominal fat | 1.14 (0.16) | 1.54 (0.19) | 1.18 (0.17) | 1.25 (0.19) | 1.17(0.15) | 1.55(0.17) | 1.22(0.16) | 1.14(0.18) | − 13.3 |
| Leptin ng/ml | 4.50 (0.67) | 1.14 (0.77) | 2.30 (0.70) | 0.92 (0.73) | 3.67(0.51) | 1.94(0.58) | 2.17(0.51) | 1.33(0.54) | − 37.5 |
| Adiponectin ng/ml | 57.8(10) | 75.7(12) | 61.1(11) | 69.3(11) | 61.3(8.7) | 74.5(10) | 70.2(9.3) | 56.1(10) | −7.01 |
| Triglycerides ng/dl | 54.3(46) | 116(53) | 155(48) | 55.4(50) | 59.0(46) | 119(53) | 146(49) | 56.7(50) | 14.0 |
| Glucose mg/dl | 78.0(10) | 90.9(12) | 77.0(10) | 65.9(11) | 81.3(6.1) | 79.7(7.2) | 76.3(6.4) | 72.8(6.8) | −7.40 |
| Insulin mIU/l | 45.2(9.4) | 49.2(23) | 14.1(3.6) | 16.9(2.1) | 43.3(11) | 52.8(12) | 10.9(11) | 19.4(12) | −68.6 |
| HOMA-IR | 9.91(3.0) | 11.4(3.4) | 2.95(3.1) | 2.81(3.2) | 9.34(2.9) | 12.4(3.4) | 1.93(3.1) | 3.76(3.2) | −73.8 |
| 24 h Activity counts | 196840 (44838) | 211135 (51774) | 251219 (46832) | 165837 (49117) | 202632 (33845) | 229537 (39206) | 206816 (36258) | 191169 (37346) | −7.91 |
| Nighttime (2400–600 h) Activity counts | 12251 (4201) | 19193 (4851) | 7785 (4388) | 11209 (4601) | 10714 (2025) | 14460 (2370) | 11938 (2142) | 12745 (2217) | −1.95 |
| Daytime (900–1700 h) activity counts | 93972 (28315) | 98697 (32696) | 151951 (29574) | 80471 (31018) | 97332 (19059) | 119354 (22206) | 116300 (20569) | 97064 (21011) | −1.53 |
| Locomotion (frq/h) | 47.7(5.3) | 37.1(6.1) | 42.3(5.5) | 35.3(5.8) | 44.7(3.4) | 41.8(4.0) | 40.0(3.5) | 37.2(3.7) | −10.8 |
Values are presented as mean (SEM).
a
Adjusted means (Pretreatment values as covariates).
b
Nondep = monkeys exhibiting little or no depressive behavior.
c
Dep = monkeys exhibiting depressive behavior.
d
% difference calculated from adjusted sertraline- and placebo-group means, boldface indicates a significant 2 (Placebo, Sertraline) × 2 (Nondepressed, Depressed) analyses of covariance (Pretreatment values as covariate) main effect of treatment (p < 0.05).